Analyst Ratings January 28, 2026

Evercore ISI Keeps Outperform on Amphenol After Strong Quarter; Guidance Lifted by CCS Deal

Robust revenue, margin expansion and record orders underpin analyst conviction as management raises near-term outlook

By Hana Yamamoto APH
Evercore ISI Keeps Outperform on Amphenol After Strong Quarter; Guidance Lifted by CCS Deal
APH

Evercore ISI has reiterated an Outperform rating and set a $165.00 price target on Amphenol Corporation after the company posted quarterly results that beat consensus. Amphenol delivered record sales and orders, marked margin improvement, and offered March-quarter guidance that includes revenue from its newly closed CCS acquisition.

Key Points

  • Amphenol reported quarterly revenue of $6.44 billion and EPS of $0.97, beating consensus estimates of $6.19 billion and $0.93.
  • Record orders reached $8.43 billion, up 68% year-over-year and up 38% sequentially, producing a book-to-bill ratio of 1.31x.
  • Management guided March-quarter sales to $6.9-7.0 billion and EPS to $0.91-0.93, including about $900 million of revenue from the CCS acquisition.

Evercore ISI maintained its Outperform rating on Amphenol Corporation (NYSE:APH) and left its price target at $165.00 following the company's latest quarterly results, which outstripped analyst expectations.

For the quarter, Amphenol reported revenue of $6.44 billion and earnings per share of $0.97, topping consensus forecasts of $6.19 billion in revenue and $0.93 in EPS. Sales for the December quarter rose 49.1% year-over-year, including 37% organic growth, with management citing strength in IT Datacom and investments tied to artificial intelligence as primary contributors.

Orders hit a record $8.43 billion, up 68% from the prior year and up 38% sequentially, producing a book-to-bill ratio of 1.31x. The company also posted notable margin expansion: gross margin was 38.2%, an improvement of 393 basis points year-over-year, while operating margin widened to 27.5%, up 513 basis points.

Amphenol provided forward guidance for the March quarter that exceeded street expectations. The company projected sales in a $6.9 billion to $7.0 billion range versus consensus of $6.55 billion, and earnings per share of $0.91 to $0.93 compared with an expected $0.89. Management stated that the guidance incorporates roughly $900 million of revenue from the recently completed CCS acquisition.

The CCS deal, which closed in early January, is forecast by the company to generate $4.1 billion in revenue and to contribute about $0.15 to EPS. Amphenol said the acquisition broadens its fiber-optic capabilities across the interconnect spectrum.

In additional disclosures, Amphenol reported fourth-quarter 2025 results that marked a record $6.4 billion in sales and EPS of $0.97. Despite the stronger-than-expected financial performance, the stock fell noticeably in pre-market trading; the company did not provide a detailed explanation for the intraday price movement.


Context and takeaway - The quarter combined outsized revenue growth, order momentum and margin expansion, while management raised near-term sales and EPS guidance by factoring in the CCS acquisition. Investors received both the beat on results and a higher outlook for the March quarter, even as early trading reacted negatively for reasons the company did not detail.

Reporting limitations - The company has not provided further detail explaining the pre-market share movement following the earnings release.

Risks

  • Pre-market share price declined despite positive results - market reaction may reflect short-term trading dynamics rather than company fundamentals; impacts equity investors.
  • Guidance depends materially on the recently closed CCS acquisition, which contributes approximately $900 million to March-quarter revenue and an estimated $0.15 to EPS; impacts investors and communications around M&A execution.
  • Continued reliance on strength in IT Datacom and artificial intelligence investments for organic growth may concentrate exposure in technology-related end markets; impacts technology and communications sectors.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026